Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells - PubMed (original) (raw)

Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells

C Marth et al. Br J Cancer. 1997.

Free PMC article

Abstract

In ovarian carcinoma cells, the combination of interferon-gamma (IFN-gamma) and cisplatin (cDDP) has been reported to result in a synergistic amplification of antiproliferative activity. To assess whether IFN-gamma may also prevent the occurrence of cisplatin resistance, the human ovarian carcinoma cell line HTB-77 was treated repeatedly in an intermittent fashion with either cisplatin alone (HTB-77cDDP) or cisplatin plus IFN-gamma (HTB-77cDDP + IFN). After 8 months of treatment, both new lines (HTB-77cDDP or HTB-77cDDP + IFN) were found to be three times more resistant to cisplatin than the wild-type cells (HTB-77wt). IFN-gamma could not prevent the development of cisplatin resistance. Interestingly, both HTB-77cDDP and HTB-77cDDP + IFN cells were also less IFN-gamma sensitive than the parental line. Both cisplatin-resistant lines expressed p185HER-2 and HER-2 mRNA at a higher concentration than the HTB-77wt cells. IFN-gamma was in all three HTB-77 cell lines able to suppress the HER-2 message and its encoded protein. The expression of IFN-gamma-induced antigens, namely CA-125 and class II antigens of the major histocompatibility complex (HLA-DR), was markedly augmented by IFN-gamma in all three lines, whereby the most prominent effect was seen in HTB-77cDDP and HTB-77cDDP + IFN.

PubMed Disclaimer

Cited by

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.
Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C. Windbichler GH, et al. Br J Cancer. 2000 Mar;82(6):1138-44. doi: 10.1054/bjoc.1999.1053. Br J Cancer. 2000. PMID: 10735496 Free PMC article. Clinical Trial.
Chemoresistance and targeted therapies in ovarian and endometrial cancers.
Brasseur K, Gévry N, Asselin E. Brasseur K, et al. Oncotarget. 2017 Jan 17;8(3):4008-4042. doi: 10.18632/oncotarget.14021. Oncotarget. 2017. PMID: 28008141 Free PMC article. Review.
Identification of genes differentially expressed in association with acquired cisplatin resistance.
Johnsson A, Zeelenberg I, Min Y, Hilinski J, Berry C, Howell SB, Los G. Johnsson A, et al. Br J Cancer. 2000 Oct;83(8):1047-54. doi: 10.1054/bjoc.2000.1420. Br J Cancer. 2000. PMID: 10993653 Free PMC article.
A chemotherapy response prediction model derived from tumor-promoting B and Tregs and proinflammatory macrophages in HGSOC.
Xi Y, Zhang Y, Zheng K, Zou J, Gui L, Zou X, Chen L, Hao J, Zhang Y. Xi Y, et al. Front Oncol. 2023 Jul 14;13:1171582. doi: 10.3389/fonc.2023.1171582. eCollection 2023. Front Oncol. 2023. PMID: 37519793 Free PMC article.
An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy.
Qi L, Li Y, Qin Y, Shi G, Li T, Wang J, Chen L, Gu Y, Zhao W, Guo Z. Qi L, et al. Br J Cancer. 2016 Dec 6;115(12):1513-1519. doi: 10.1038/bjc.2016.370. Epub 2016 Nov 17. Br J Cancer. 2016. PMID: 27855439 Free PMC article.

References

1. Nature. 1986 Jan 16-22;319(6050):230-4 - PubMed
1. J Biol Chem. 1996 Jul 19;271(29):17247-52 - PubMed
1. Anticancer Res. 1989 Mar-Apr;9(2):461-7 - PubMed
1. Cancer Cells. 1990 Feb;2(2):35-43 - PubMed
1. Cancer Res. 1990 Nov 1;50(21):7037-41 - PubMed

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells - PubMed (original) (raw)